Results 1 to 3 of 3

Thread: Boston Life Sciences to Hold Conference Call on May 22, 2002

  1. #1

    Boston Life Sciences to Hold Conference Call on May 22, 2002

    Boston Life Sciences to Hold Conference Call on May 22, 2002


    BOSTON--(BW HealthWire)--May 21, 2002--Boston Life Sciences, Inc. (NASDAQ:BLSI) announced that it will hold an investor's conference call on Wednesday, May 22, at 11:00 am EDT.

    During the call, the company will discuss the Notice of Allowance of claims and the patent application for the use of Inosine to treat stroke and spinal cord injuries. To participate in the conference call, please dial (800) 556-3831 in the U.S. and Canada, or for International callers (972) 512-0694. All participants must enter the following passcode to partake in the call: 70549.

    The conference call will also be taped and may be heard by dialing (888) 746- 9011 within the U.S. and Canada, or International callers may dial (972) 512-0694 and enter the following passcode: 01665. The audio recording of the call will be available through May 24, 2002 until 11:59pm.

    The management of the company will also answer questions about the development of diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as Troponin for the treatment of solid tumors. Progress and developments on other projects will also be discussed.

    BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: ALTROPANE(TM) and FLUORATEC(TM) radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

    Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products.

    All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.

    CONTACT:

    Boston Life Sciences, Inc.

    Corporate

    Investor Relations

    Mollie Richardson, 617/425-0200

    IR@bostonlifesciences.com

    SOURCE: Boston Life Sciences, Inc.

  2. #2

    For

    A recap of BLSI's conference call held today call either:

    1-888-556-3831, or 972-512-0694 (passcode 01665)

    Very informative concerning neuroscience.

    Onward and Upward!

  3. #3
    Senior Member Jeremy's Avatar
    Join Date
    Jul 2001
    Location
    Canada
    Posts
    588
    Boston Life Sciences Clarifies Recent Patent Allowance for Inosine -- Allowance of claims is related to treatment of stroke injury. Claims related to treatment of other CNS injuries, submitted separately, are pending



    Story Filed: Thursday, May 23, 2002 1:11 PM EST

    BOSTON, May 23, 2002 (BUSINESS WIRE) -- As announced previously, Boston Life Sciences, Inc. (NASDAQ:BLSI) has received written Notice of Allowance of claims in one of the Company's licensed patent applications pertaining to Inosine. The allowed claims cover the use of Inosine to treat stroke injury in a human subject by administration into the fluid surrounding the brain and spinal cord. The use of Inosine to treat a variety of other Central Nervous System (CNS) injuries, including spinal cord injury, is covered by claims in eight other licensed patent applications, all of which are in active prosecution with the Patent and Trademark Office.

    BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: ALTROPANE(TM) and FLUORATEC(TM) radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

    Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.


    CONTACT: Boston Life Sciences, Inc.
    Marc Lanser, M.D.
    Chief Scientific Officer
    617.425.0200

    "If the wind could blow my troubles away. I'd stand in front of a hurricane."

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •